We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Monoamine Transporter Function and Autonomic Regulation During Psychodynamic Psychotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00594711
Recruitment Status : Completed
First Posted : January 16, 2008
Last Update Posted : October 31, 2011
Information provided by (Responsible Party):

January 7, 2008
January 16, 2008
October 31, 2011
January 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00594711 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Monoamine Transporter Function and Autonomic Regulation During Psychodynamic Psychotherapy
Not Provided

Outcome of psychodynamic psychotherapy measured by [123I] nor-B-CIT SPET imaging

Background Psychodynamic psychotherapy is a widely practised form of psychotherapy in the treatment of depression. There is evidence that serotonin transporter (SERT) densities are altered in depression. Preliminary observations have suggested that SERT function may recover in connection with dynamic psychotherapy.

The objective was to determine whether SERT densities change in relation to clinical recovery during psychodynamic psychotherapy.


Method Twenty six drug-naïve currently depressed (moderate/severe) patients with no previous treatment were recruited for the study. The baseline study included a group of 18 healthy controls. The patients were randomised into psychotherapy and waiting-list control groups. For controls, psychotherapy was started after a 6-month waiting period. [123I] nor-B-CIT SPET imaging was performed at baseline and after 12 months of psychotherapy. For the controls, additional imaging was performed after the 6-month waiting period.

Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
DNA, creatine, B-vitamin,BP from blood samples.
Non-Probability Sample
Patiens of clinic
Not Provided
  • 1
  • 2
Joensuu M, Ahola P, Knekt P, Lindfors O, Saarinen P, Tolmunen T, Valkonen-Korhonen M, Vanninen R, Jääskeläinen T, Virtala E, Kuikka J, Tiihonen J, Lehtonen J. Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression. Psychiatry Clin Neurosci. 2016 Jan;70(1):34-41. doi: 10.1111/pcn.12335. Epub 2015 Sep 22.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2008
Not Provided

Inclusion Criteria:

  • depression

Exclusion Criteria:

  • antidepressive medication
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Taru Grohn, Kuopio University Hospital
Kuopio University Hospital
University of Eastern Finland
Principal Investigator: Pirjo Saarinen, Ph.D. Kuopio University Hospital
Study Director: Johannes Lehtonen, Ph.D Kuopio University Hospital
Study Chair: Lehto Soili, MD Kuopio University Hospital
Study Chair: Minna Valkonen-Korhonen, Ph.D Kuopio University
Study Chair: Pasi Ahola, MD Kuopio University
Study Chair: Mikko Joensuu, MD Kuopio University Hospital
Study Chair: Tommi Tolmunen, Ph.D. Kuopio University Hospital
Kuopio University Hospital
October 2011